Introduction: To estimate the value of interventions in multiple sclerosis (MS) -where lifetime costs and outcomes cannot be observed -outcome data have to be combined with costs. This requires that cost data be regularly updated.
Introduction
Economic studies in health care have a long tradition in academic life in the Netherlands and have officially been included into decision-making in 2005 with a policy on access to insurance. Guidelines on how to perform economic evaluations for new pharmaceuticals were finalised and adopted in 2005 (first version 1999) and updated in 2016. 1 The number of published studies in health services policy research, cost of illness studies and economic evaluations is consequently high compared to other countries. As in many other countries, multiple sclerosis (MS) has been well studied since the introduction of the first diseasemodifying treatments (DMTs) in early 2000 and the intense debate about their cost-effectiveness. 2 The availability of DMTs and improved imaging techniques of the central nervous system have led to changes in patient management and a focus on earlier and better diagnosis and adjustments in the diagnostic criteria themselves. One of the consequences in this regard is that the recorded prevalence of the disease is quite different from that estimated two or three decades ago. 3 Kramer and colleagues estimated that incidence had increased from 4/100,000 to 9/100,000 population. 4 Recent scientific research on the prevalence of MS in the Netherlands is lacking but based on national databases the prevalence is currently estimated at around 100/100,000 population. With diagnostic criteria being revised several times resulting in increased sensitivity, and a definite diagnosis already possible after a clinically isolated event, 5 one must also expect a different distribution of the type of MS and the severity of the disease than 10 years ago: a larger proportion of patients with relapsing remitting disease and thus of patients in the early stages of the disease and with less disability (a low score on the Expanded Disability Status Scale (EDSS)). This phenomenon is known as stage migration and described in many diseases including MS. 6 It is therefore important to update the information on the burden of MS, and the study presented here is part of a European-wide effort to update information on the burden of illness of MS in 16 countries, endorsed by the European Platform of MS Societies (EMSP) and carried out with the support of national MS societies. 7 It uses a similar methodology as the last European survey in 2005 that also included the Netherlands. 8, 9 Materials and methods The detailed methodology for the European survey is published separately. 9 We therefore only provide a short summary of the general methods, and issues specific to the Netherlands.
Data
The study aimed to estimate the costs of all health care and other resource utilisation related to MS: hospitalisation, rehabilitation, consultations, diagnostic procedures and tests, medication, community care, family support and production losses (sick leave, early retirement, invalidity). In addition, information on major symptoms such as fatigue and cognitive difficulties, health-related quality of life (HRQoL) as well as self-assessed disability using descriptions based on the EDSS was collected.
Data were collected with a standard questionnaire, at a single point in time, for a retrospective period of time. The latter was varied depending on the question to minimise recall bias: 1 month for use of drugs, community services and family help; 3 months for hospitalisation, consultations, tests, sick leave and relapses; and 12 months for major investments. Resource utilisation is reported for these time periods, while cost calculations are annualised.
Disease information such as the type of MS, disability (EDSS), HRQoL, utility (EuroQol-5 dimensions (EQ-5D) 10 ), symptoms (fatigue, cognitive difficulties) and the effect of MS on work related to the current day or week. For comparability across countries, 7 utilities are estimated with the original value set developed in the United Kingdom. 11 In the Netherlands, Versteegh and colleagues established a national tariff applying the same methodology as used for the UK tariff, and we therefore also present utilities established with the local tariff. 12 The handling of missing data for the cost calculation is explained in more detail in the paper describing the methods. 9 For resource use, we present actual answers without any imputation for missing answers. Also, no imputations are made for missing information on disease status, symptoms and HRQoL.
Costs
Costs are calculated from the societal perspective, including all costs regardless of who ultimately is responsible for them. Patient co-payments and patients' out-of-pocket expenses are thus included. The cost of a relapse is calculated as the difference in quarterly costs between patients with or without a relapse and an EDSS score of 0 to 6; patients who were unsure were excluded from the estimation. Invalidity, early retirement and DMT costs are not considered in this calculation, as these are unlikely to be affected within 3 months.
Although the Dutch guidelines for economic studies demand that production losses be estimated with the friction cost method, 1, 13 these are presented here using the human capital approach. In the first, costs are only calculated up to a time point when an individual leaving the workforce would be replaced in the labour market (friction period); 13 in the latter, costs are considered for an individual who will no longer contribute to national production. 14 As a consequence, production losses estimated with the friction method are substantially lower. The Netherlands and Belgium are the only countries applying the friction cost method, 15 and for reasons of consistency in this current European study, production losses are calculated with the same method in all 16 countries.
Unit costs for the individual resources were taken from public sources and are described elsewhere. 9 Results are reported in EUR 2015.
Patients
The objective was to include a sample where all levels of disease severity (defined by EDSS) were represented in sufficient numbers to permit analysis, rather than a prevalence sample. This allows highlighting how costs and HRQoL change as the disease progresses and provides the necessary data for costeffectiveness analysis of treatments that are expected to change the course of the disease. Mean results may thus not be representative and should neither be extrapolated directly to national costs nor be compared directly to the results in earlier studies. We therefore report results by disease severity groups only (mild MS EDSS 0-3, moderate MS EDSS 4-6.5, severe MS EDSS 7-9).
Data collection
In anonymous surveys, participation will depend heavily on the methods used for the survey: collecting data in MS centres tends to overestimate the number of patients with early but severe disease and on treatment with DMTs; 16 collecting data from members of patient organisations may lead to the opposite. Internet surveys will bias towards younger patients with better education, while postal surveys may recruit older patients with more advanced disease.
The Dutch participants in the study presented here were members of a patient organisation (the Dutch MS Vereniging) and all but one responded to the survey online. The data were collected during the summer and fall of 2015. The MS society invited 1000 individuals by email, and after a reminder, the response rate reached 38%.
Results
A total of 382 evaluable responses were received, all but one online, which reduced the number of missing data considerably as a majority of answers were mandatory to continue responding. The geographical distribution of respondents represented almost perfectly the proportion of inhabitants of the different regions. 17 Table 1 provides the details on demographics, employment and disease.
Demographics and employment
The age of respondents in the Netherlands ranged from 22 to 82 years (mean: 54.0, median: 54.5, standard deviation (SD): 10.5). Women represented 72% of the sample; 80% lived with their family and four patients lived in a nursing home at the time of the survey. Education levels in our sample were comparable to the general population of that age group: 2% of patients had basic education, 31% had a secondary, 41% a professional and 27% a university degree. This compares to 40% of the population with upper secondary education and 32% with tertiary education. 18 Despite the relatively high mean age, the vast majority of patients in the sample were below retirement age (defined as effective retirement age, 62.3 for women and 63.6 for men 19 ): 309 patients (81%). However, of these, only 96 patients (31%) patients were employed or self-employed. Two patients above retirement age also worked, bringing this group to 98 patients (or 26% of the full sample), with a mean age of 48.9 years. This compares to an employment rate of 67.1% in the general population aged 15-75 years in 2015. 20 In addition, all of these patients worked parttime, on average 17 hours per week, and 40% did so because of MS. In the general population about half of the employed work part-time, the highest rate in Europe. 20, 21 Sick leave during the past 3 months was reported by 10 patients, with a mean duration of 8.6 days.
Employment decreased rapidly with advancing disease, as shown in Figure 1 . Of non-employed patients, three-quarters indicated MS as the reason.
Most patients felt that MS affected their productivity at work (82%) and only 14% indicated that they had no problems, while 4% had not answered the question. The severity of the effect covered the entire visual analogue scale (VAS) range from 0 to 10, with a mean of 3.8 (SD 2.9) ( Figure 2 ). Fatigue was considered the most bothersome symptom (71%), followed by difficulties thinking (31%), mobility (29%), pain (23%) and low mood (7%).
Disease information is summarised in Table 1 . The mean EDSS in the sample was 4.9 (SD 2.3), and selfreported EDSS scores covered the entire range, with the exception of EDSS 0 (10 patients) and EDSS 9 (5 patients). The mild group represented 30% of the sample, the moderate group 42% and the severe group 28%.
The proportion of patients with relapsing-remitting multiple sclerosis (RRMS) was 35%, with secondary progressive multiple sclerosis (SPMS) 35% and with primary progressive multiple sclerosis (PPMS) 27% (3% missing). The proportion stating PPMS is considerably higher than what would be expected and what has been found in recent studies, 3, 22 and suggests, as we found in previous studies, that patients were insecure in their answers regarding the type of disease. We therefore did not include the disease type in our analyses and focus on EDSS levels instead. DMTs were used by 26% of the sample, with usage declining with higher EDSS levels, as expected (Table 1) . Among users, 13% were on their first DMT treatment; first-generation DMTs were used by 51% of users ( Table 2) .
Relapses in the preceding 3 months were reported by 67 patients (18%) of which half occurred in the past month (Table 1) . However, 95 patients (25%) were unsure whether they had a relapse or not, and we assumed that the answer was no. Thus, the mean relapse rate over a 3-month period was estimated at 0.3 (SD: 0.7). Corticosteroids were administered to 21 patients (31%) with relapses, predominantly as infusions (18 patients).
Symptoms and HRQoL
Fatigue and cognitive difficulties were an issue for a majority of patients, and both were related to disease severity ( Figure 2 ). Fatigue was present in 96% of patients. The mean VAS score was 6.2 (SD: 2.4) for the sample, 5.3 for patients with mild disease, 6.4 for patients in the moderate group and 6.6 for patients in the severe group. Cognitive difficulties were reported by 73% of all patients. The mean VAS score in this group was 5.4 (SD: 2.1) overall, 5.2 in the mild, 5.5 in the moderate and 5.3 in the severe group. For the full study sample (assigning 0 to the group with no problems), the mean score was 3.9 (3.6, 4.3, 3.7).
The detailed answers to the EQ-5D indicated that both the severity and the domains affected changed with advancing disease. Self-care was unaffected in patients with mild disease, but declined very rapidly with advancing disease; mobility, pain and usual activities presented problems for almost all patients already in moderate disease; most noticeably, anxiety/ depression was present in 30%-40% of the patients at all levels of disease severity (Figure 3 ).
Utility
Utility declined with disease severity (EDSS) (Figure 4 ). Mean utility in this specific sample of EDSS: Expanded Disability Status Scale. Proportion of patients below retirement age employed or self-employed. In all, 309 patients (81%) were below retirement age and of these, 31% were employed or self-employed. Among these, 15 patients were on long-term absence. patients was 0.555 and 0.637 using the UK and Dutch value sets, respectively.
Resource utilisation
Resource utilisation is presented in Table 3 . Hospitalisation was infrequent in this sample. During the preceding 3 months, 19 patients (5%) were admitted as inpatients. Of these, 12 patients (3%) were admitted to the neurology ward, on average 1.7 (SD 1.6) times and for a mean of 3.7 (SD 2.5) days. Admission to a general ward was reported for 12 patients (3%). Day admissions occurred for 35 patients (9%), on average every 3 weeks. Inpatient or day admissions to rehabilitation centres were reported for seven patients (2%).
The majority of patients (268, 70%) had a consultation during the past 3 months, most often with a neurologist (44%), an MS nurse (21%), a general practitioner (15%) or a physiotherapist (33%). Investigations and tests were needed by 70 patients (18%), and medications for MS and MS-related symptoms were used by 272 patients (71%) during the past month. Drugs other than DMTs were used by 68 (18%) of patients, Proportions of patients at different levels of disease severity experiencing difficulties in the five domains of the EQ-5D. All domains present problems for patients already in mild disease, except the ability for self-care that however declines very rapidly with worsening disease. Anxiety/depression is present with similar severity at all stages of the disease.
predominantly treatments for walking, spasticity and pain (13%). Non-prescription drugs were used by 221 patients (58%).
Investments in equipment and devices to aid patients' mobility were made during the past 12 months for or by 123 patients (32%), most often for modifications to the car or the house and walking aids.
The use of community and social services and of informal care increased with increasing disease severity. Community services were used by 18% of patients, most frequently home help and transportation. Help from family was used by 52% of patients, on average 16.8 days per month and 3.3 hours per day ( Figure 5 ).
Costs
Total mean annual costs per patient for patients with mild, moderate and severe disease and by EDSS score are presented in Figure 6 and Table 4 .
The average cost of a relapse for patients with an EDSS up to 6 was estimated at €2977. All types of costs increased during a relapse, with day admission representing 30% of the additional cost, informal care 21%, and consultations and investments 13% each (Figure 7) .
Discussion
This study provides an update to current understanding of the burden of MS on patients, the health care system and society in general in the Netherlands based on a cross-sectional survey conducted in 2015.
Despite one of the best response rates in the 16-country survey (38%), the Dutch sample was one of the smallest due to the limitation of the electronic contact list of the MS Society (1000 contacts). However, the sample was geographically representative, with educational levels comparable to the general population, well spread over the entire disease severity, and with very few missing data due to only online responses. Our estimates of costs and utilities as well as symptoms by disease severity can therefore be considered representative.
Disease symptoms and utility were very similar to those found in all the other countries, attesting to the fact that the severity of the disease affects patients in the same way regardless of jurisdiction or heath care systems. Thus, family support (informal care) was found to be at a similar level as in the other countries as well.
Contrary to this, consumption of health care resources in the Netherlands was very different from most countries in the study. Hospitalisation was minimal, with EDSS: Expanded Disability Status Scale. Utility by EDSS level estimated with the EQ-5D using both the UK and Dutch value sets (Dolan, ref NL) . Utility is calculated by relating the scores of the five domains (1 = no problems; 2 = some problems; 3 = severe problems) to a health state valuation system established with the general population. The differences in the valuations may be partly due to small methodological differences, partly due to specific national characteristics where Dutch scores are slightly higher, particularly in severe disease. the relapsing remitting phase of the disease, the only phase in which DMTs have been proven effective, the reported 26% on DMT seems to support this although there may be some under-treatment.
On the other hand, only 31% of patients of working age were actually employed, none of them worked full-time and 15 of the 96 participants concerned were on long-term sick leave. In Belgium, 44% of patients worked, a quarter of them full-time, while in Germany the proportions were 51% and 35%. The low workforce participation in the Netherlands may be influenced by the relatively generous invalidity benefit scheme and frequency of part-time employment, not only by the disease itself. The consequence of these two factors, low health care costs and low work participation rate, is that production losses represent a much larger proportion of costs in mild and moderate disease than in the other European countries.
A similar picture of resource consumption was already found in the 2005 survey 2 although participants in that earlier study had been recruited from MS clinics and were thus considerably younger and with less disability: 47 years compared to 54 years in this study, and a mean EDSS of 3.9 compared to 4.9. Direct health care costs were low compared to other countries, but higher than in the current survey, as would be expected for younger patients recruited by clinics. 16 Inpatient admissions occurred in 8% of patients (5% in the current study); 57% had consultations with neurologists (compared to 44%); 35.5% were treated with DMTs (compared to 26%) and 15% had a brain magnetic resonance imaging (MRI) compared to 11%. Nevertheless, production losses (calculated with the human capital method) dominated costs already in early disease as well, with informal care and community services dominating in severe disease.
Overall, the resource utilisation reflects the clinical needs of patients, but they also have to be seen in the light of the organisation of the Dutch health care system, medical traditions and cultural norms.
The mean time from first symptoms to diagnosis in the Dutch sample was slightly above 8 years which is long in view of recent research regarding the benefits of early intervention. 23 However, it is a reflection of the mean age of the sample with patients having been diagnosed 12-15 years ago. That is just around the time of the introduction of the McDonald criteria, which was a true revolution in the diagnostic process. 24 The first symptoms were reported to have occurred many years earlier, which may add to the delay. In addition, retrospective reporting of first symptoms may be subject to recall bias and affect the estimated diagnostic delay. In the younger sample in 2005, time to diagnosis was 6 years. DMTs: disease-modifying treatments; EDSS: Expanded Disability Status Scale. Mean total 3-month costs for patients below EDSS 6.5 with and without a relapse. The cost of a relapse is calculated as the difference between the two groups, excluding DMTs, invalidity and early retirement (€2977). The difference arises essentially from day admissions and sickness absences.
In conclusion, these data characterise various aspects of the burden of MS on patients and society and capture patterns of resource utilisation that could inform future policy recommendations. In addition, these data provide input into cost-effectiveness analyses for reimbursement decisions. The study reveals, and in part confirms, existing cross-cultural differences between countries. Therefore, it is crucial to use country-specific data for valid decisions.
